Literature DB >> 30746222

Choice of the surgical approach for patients with stage I lung squamous cell carcinoma ≤3 cm.

Chunji Chen1, Yiyang Wang1, Xufeng Pan1, Shijie Fu1, Yubo Shi2, Jun Yang1, Rui Wang1.   

Abstract

BACKGROUND: We tried to explore the surgical procedures for stage I squamous cell carcinoma (SCC) with a size of ≤3 cm by using the Surveillance, Epidemiology, and End Results (SEER) database. Furthermore, we investigated the relationships between the chosen surgical option and the size of SCC.
METHODS: In total, 1,147 patient data sets were collected from 2010 to 2011 using the SEER database. Afterwards, 849 patients with a pT1-2aN0M0 SCC with a size of ≤3 cm after a lobectomy or sublobectomy procedure were identified. Kaplan-Meier curves were conducted to compare the overall survival (OS) rates and the lung cancer-specific survival (LCSS) rates between the two surgical approaches. Cox proportional hazards regressions were performed to discover the independent risk factors for both the OS and LCSS rates. Lastly, subgroup analysis was stratified by the size of the SCC and then classified by the 8th edition T category.
RESULTS: The sublobectomy procedure did not demonstrate a difference for the OS rate. Additionally, it demonstrated a worse LCSS rate when compared with a lobectomy for stage I SCC. In the subgroup analysis, a lobectomy was shown to have a better survival outcome only when the SCC was >2 and ≤3 cm. Multivariable analysis showed that a size of >2 to ≤3 cm, and an age of >60 were independently associated with poorer OS while the sublobectomy procedure and pleural invasions (PI) were related with a poorer LCSS rate. In the stratification of data for the tumor size, the cox proportional analysis still confirmed the protective effects of the lobectomy in subgroups of SCCs with sizes between >2 to ≤3 cm as well as the T1c category.
CONCLUSIONS: The choice of the SCC surgery can be recommended based on the tumor size. A lobectomy procedure demonstrated a better LCSS against the sublobectomy in stage I SCC. SCC with sizes of >2 to ≤3 cm could become a pretty good indicator for lobectomy, while a sublobectomy may be an adequate substitute when the SCC size is ≤2 cm, especially for patients who cannot tolerate a lobectomy. T1c category can also suggest a lobectomy instead of sublobectomy for stage I SCC patients.

Entities:  

Keywords:  Stage I squamous cell carcinoma (stage I SCC); lobectomy; sublobectomy

Year:  2018        PMID: 30746222      PMCID: PMC6344714          DOI: 10.21037/jtd.2018.11.51

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  38 in total

1.  Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.

Authors:  F Tas; A Aydiner; E Topuz; V Yasasever; A Karadeniz; P Saip
Journal:  J Exp Clin Cancer Res       Date:  2000-12

2.  Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis.

Authors:  Y Ohta; M Oda; J Wu; Y Tsunezuka; M Hiroshi; A Nonomura; G Watanabe
Journal:  J Thorac Cardiovasc Surg       Date:  2001-11       Impact factor: 5.209

3.  The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.

Authors:  Kari Chansky; Jean-Paul Sculier; John J Crowley; Dori Giroux; Jan Van Meerbeeck; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

4.  Differences in clinicopathological and biological features between central-type and peripheral-type squamous cell carcinoma of the lung.

Authors:  Takamoto Saijo; Genichiro Ishii; Kanji Nagai; Kazuhito Funai; Junichi Nitadori; Koji Tsuta; Michiya Nara; Tomoyuki Hishida; Atsushi Ochiai
Journal:  Lung Cancer       Date:  2006-02-23       Impact factor: 5.705

Review 5.  Clinicopathologic features of peripheral squamous cell carcinoma of the lung.

Authors:  Hiroyuki Sakurai; Hisao Asamura; Shun-ichi Watanabe; Kenji Suzuki; Ryosuke Tsuchiya
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

Review 6.  Surgical management of primary lung cancer.

Authors:  Robert J McKenna
Journal:  Semin Oncol       Date:  2007-06       Impact factor: 4.929

7.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung.

Authors:  Kazuhito Funai; Tomoyuki Yokose; Gen-ichiro Ishii; Kazuhiro Araki; Junji Yoshida; Mitsuyo Nishimura; Kanji Nagai; Yutaka Nishiwaki; Atsushi Ochiai
Journal:  Am J Surg Pathol       Date:  2003-07       Impact factor: 6.394

9.  Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.

Authors:  Ajeet Gajra; Nancy Newman; Gary P Gamble; Leslie J Kohman; Stephen L Graziano
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

10.  Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis.

Authors:  Claudia Poleri; José Luis Morero; Beatriz Nieva; María Fernanda Vázquez; Cristina Rodríguez; Ernesto de Titto; Moisés Rosenberg
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

View more
  1 in total

1.  Selection of the surgical approach for patients with cStage IA lung squamous cell carcinoma: A population-based propensity score matching analysis.

Authors:  Shengteng Shao; Guisong Song; Yuanyong Wang; Tengfei Yi; Shuo Li; Fuhui Chen; Yang Li; Xiaotong Liu; Bin Han; Yuhong Liu
Journal:  Front Oncol       Date:  2022-08-23       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.